Risk Mitigation Plans Clause Samples
POPULAR SAMPLE Copied 1 times
Risk Mitigation Plans. Risk Mitigation Plans (RMPs) will be completed annually for all GSK Products. All RMPs will outline standard risk mitigation activities that will be performed and tracked for each GSK Product, regardless of the product’s relative risk ranking (Standard RMPs). Standard risk mitigation activities will consist of the monitoring activities to be conducted for each GSK Product in the upcoming year, such as monitoring of speaker programs, speaker training, advisory boards, sampling, verbatim reviews, medical information requests and ride-alongs with sales personnel. Based on the Risk Evaluation Report, products may be selected for Enhanced RMPs by either (or both) the Leadership Teams and the CLT. These RMPs will include enhanced risk mitigation activities, in addition to the standard activities (Enhanced RMPs). Enhanced RMPs will consist of activities tailored to the risks identified during the risk ranking process. For example, such activities may include increased compliance messaging from Leadership Teams, modifications to or limitations of promotional programs, or enhanced training requirements. All RMPs (whether Standard or Enhanced) will be developed by brand teams, in consultation with their respective DCOs and the CCoE, on an annual basis. Each RMP will specify the: (i) risk monitoring activities; (ii) metrics by which monitoring activities and results will be evaluated and/or measured; (iii) risk mitigation action items, if necessary; (iv) metrics by which risk mitigation activities and results will be evaluated and/or measured; (v) responsible individual(s); and (vi) expected date(s) of monitoring and/or action item completion. The RMPs will be reviewed and approved by the respective business unit Leadership Teams.
Risk Mitigation Plans. Each annual RAMP shall outline standard risk mitigation activities to be performed and tracked for each actively promoted product. Risk mitigation activities will include, at a minimum, monitoring activities to be conducted for each actively promoted Government Reimbursed Product in the upcoming year, such as monitoring of speaker programs, speaker training, advisory boards, sampling, verbatim reviews, medical information requests and ride-alongs with sales personnel. Each RAMP shall identify and explain: (i) the risk areas identified for mitigation;
Risk Mitigation Plans. A risk mitigation plan under subsection (b) shall include, at a minimum, the following:
(1) For each high-risk area identified in the com- prehensive risk assessment for the operation per- formed under subsection (b)—
(A) specific actions to mitigate or reduce such risk, including the development of alternative ca- pabilities to reduce reliance on contractor perform- ance of critical functions;
(B) measurable milestones for the implementa- tion of planned risk mitigation or risk reduction measures; and
(C) a process for monitoring, measuring, and documenting progress in mitigating or reducing risk.
(2) A continuing process for identifying and ad- dressing new and changed risks arising in the course of the operation, including the periodic reassessment of risks and the development of appropriate risk mitigation or reduction plans for any new or changed high-risk area identified.